U.S – New C0VID-19 vaccines effectiveness study conducted by CDC shows that mRNA vaccines by Pfizer-Biotech and Moderna reduce ri

According to the study, the FDA approved vaccines reduced the risk of contracting SARS-CoV-2 virus by 94% among health care workers who were fully vaccinated.

This study is the largest one to date, covering a sample size distribution of 500,000 health care personnel across 25 U.S. states, provides concrete evidence that C0VID-19 vaccines are performing as expected in the real world.

Compared to the earlier study by CDC  on health care personnel which found that effectiveness of the vaccines was at 90% after full immunization and 80% after administration of the first dose, this study has found that mRNA vaccines are 94% effective upon full immunization and 82% effective after administration of the first dose.

CDC Director, Rochelle P. Walensky, MD, MPH, said the study provided the most compelling information to date that the vaccines are performing as expected in the real world.

 “This study, added to the many studies that preceded it, was pivotal to CDC changing its recommendations for those who are fully vaccinated against COVID-19,” he added.

It is important to take a keen look on vaccine performance among health care providers. This is because they are at a higher risk of getting infected through daily exposure to the virus. Vaccination of healthcare personnel protects them and their patients against COVID-19 and ensures critical health services continue to be provided.

This study provides a precise vaccine effectiveness estimate with narrower confidence intervals than earlier findings. Further, the findings support CDC’s recommendations that everyone should get both doses of an mRNA COVID-19 vaccine to get the most protection.

This assessment is part of CDC’s comprehensive strategy of using complementary methods to understand how COVID-19 vaccines are working in different populations and real-world settings.

On May 12, CDC expanded COVID-19 vaccination recommendations to include adolescents under the U.S. Food and Drug Administration’s Emergency Use Authorization. These adolescents are now authorized to receive the Pfizer-BioNTech COVID-19 vaccine.

CDC has several surveillance networks that will continue to assess how well FDA-authorized COVID-19 vaccines are working in real-world conditions in people of different age groups, including children and adolescents.